The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

@article{Palayekar2007TheER,
  title={The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer},
  author={Meena J Palayekar and Thomas J. Herzog},
  journal={International Journal of Gynecologic Cancer},
  year={2007},
  volume={18},
  pages={879 - 890}
}
Epidermal growth factor receptor (EGFR) inhibitors are a new biologically targeted therapy, which may offer new hope in the treatment of patients with advanced or recurrent ovarian cancers. In this review, we summarize and discuss the results of research to date on EGFR inhibitors with particular emphasis on ovarian cancer. We reviewed data identified by searches of MEDLINE, PubMed, and abstracts from the proceedings of the American Society of Clinical Oncology meetings from 1998 to 2006, with… Expand
Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma
  • H. Hirte
  • Medicine
  • OncoTargets and therapy
  • 2013
TLDR
Ongoing and future studies of erlotinib and other agents blocking EGFR will need to define mechanisms resulting in resistance to such interventions, and to validate biomarkers of response to identify patients most likely to benefit from such approaches. Expand
Pertuzumab for the treatment of ovarian cancer
TLDR
This review examines the recent clinical trials results and associated preclinical studies that support the utility of pertuzumab in this disease and compares its activity with that of other clinically evaluated HER2 inhibitors. Expand
Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
TLDR
More comprehensive, systematic, and well-defined approaches are needed to dissect the roles that EGFR plays in the complex signaling processes in ovarian cancer as well as to identify biomarkers that can accurately predict sensitivity toward EGFR-targeted therapeutic agents. Expand
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
TLDR
EGFR inhibitors, including pertuzumab, may add activity to conventional chemotherapy for treatment of platinum-resistant ovarian cancer, and certain subsets of women with particularly aggressive tumours resistant toventional chemotherapy may benefit from EGFR inhibitor treatment. Expand
Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy.
TLDR
A review of recent advances in the roles and other associated pathways in cancer stem cells (CSCs) and breast cancer with a specific focus on breast cancer and breast CSCs. Expand
Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells
TLDR
Results suggest that WEB2086 and AG1478 are synergistic in ovarian cancer cells with high expression of both PAFR and EGFR, which may have important therapeutic implications in the treatment of ovarian cancer patients. Expand
Targeting the EGF Receptor for Ovarian Cancer Therapy
TLDR
Contributions of EGF receptor activation to ovarian cancer pathogenesis and the status of E GF receptor inhibitors and EGF receptors targeted therapies in ovarian cancer treatment are discussed. Expand
F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies
TLDR
Results suggest that F84 could be a potential drug candidate for the treatment of human gynecologic malignancies, related to inhibition of EGFR signaling pathway, delay in cell cycle progression and a G1 arrest together with a partial G2/M block and induction of apoptosis. Expand
Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways
  • D. Hiss
  • Medicine
  • Journal of oncology
  • 2012
TLDR
A review of recent developments in understanding of the interrelationships among selected ovarian tumor biomarkers, heterogeneous expression signatures and related molecular signal transduction pathways, and their translation into more efficacious targeted treatment rationales is profile. Expand
Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.
TLDR
An update on recent research on the therapeutic opportunities presented by mutational alterations to the epidermal growth factor receptor (EGFR) and phosphatidylinositide-3-kinase (PI3K/AKT/mTOR) pathways is provided and the role of the deficient BRCA1/2-mediated homologous recombination (HR) pathway is presented. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 118 REFERENCES
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
TLDR
Current preclinical and clinical evidence on monoclonal antibodies, immunoconjugates, anti-EGF vaccine, tyrosine kinase inhibitors, and selective inhibitors of this family of receptors are examined. Expand
Epidermal growth factor receptor inhibition and non-small cell lung cancer.
TLDR
Patients with Asian background, women, non-smokers, and patients with adenocarcinoma had higher response rates than other patients, and the differences may be due to an association between the clinical characteristics and EGFR mutations. Expand
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
TLDR
Although the erb tyrosine kinase inhibitors are attrative agents to use in treating non-small cell lung cancer because of their relatively benign toxicity profile, more data are needed to define the role of these agents in non- Small Cell lung cancer. Expand
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.
TLDR
It is shown here that somatic deletions in the tyrosine kinase domain of EGFR were associated with increased EGFR gene copy number in NSCLC and other factors inNSCLC cells, such as high expression of ErbB family members, may constitutively activate AKT and sensitize cells to EGFR inhibitors. Expand
Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer
  • F. V. von Eyben
  • Medicine
  • Critical reviews in clinical laboratory sciences
  • 2006
TLDR
Patients with Asian background, women, non-smokers, and patients with adenocarcinoma had higher response rates than other patients, and the differences may be due to an association between the clinical characteristics and EGFR mutations. Expand
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
  • F. Ciardiello, G. Tortora
  • Medicine, Biology
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
TLDR
A mini-review describes the EGFR inhibitors in clinical development and preliminary results from Phase I and II trials in patients with advanced disease demonstrate that ZD1839 and OSI-774 have an acceptable tolerability profile and promising clinical efficacy in Patients with a variety of tumor types. Expand
Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer
TLDR
The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC) and erlotinib has shown a survival advantage in patients with advanced NSCLC. Expand
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
  • R. Herbst, A. Maddox, +9 authors P. LoRusso
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Rash and diarrhea, generally mild and tolerable at doses <or= 600 mg/d, were DLTs at 800mg/d (maximum-tolerated dose), and Pharmacokinetic analyses confirmed suitability of once-daily oral dosing. Expand
The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma
TLDR
In a series of 106 patients with epithelial ovarian cancers in FIGO stages IA-IIC, a number of known prognostic factors were studied in relation to two important growth factor receptors for oncogenesis (HER-2/neu and EGFR). Expand
Clinical activity of GW572016 in EGF10003 in patients with solid tumors.
  • M. Versola, H. Burris, +6 authors N. Spector
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
QD administration of GW572016 is well tolerated with evidence of clinical activity in this heavily pre-treated population and serum VEGF levels represent an easily accessible pharmacodynamic endpoint forGW572016 therapy since VEGf is regulated in part by ErbB receptor signaling. Expand
...
1
2
3
4
5
...